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CONCLUSION: The ICER for the maraviroc strategy is com-
parable to values reported for use of antiretrovirals in similar
populations, and was most favorable for individuals with few
active treatment options.
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OBJECTIVE: Nosocomial pneumonia (NP), the second most
common hospital-acquired infection in the US, is associated
with excess morbidity, mortality, hospital days and health care
costs. The objective of this study was to compare treatment
costs and cost-effectiveness of doripenem (currently under FDA
review for NP indication) to two common NP treatments.
METHODS: Outcomes for a population of hospitalized
patients with NP, including a subset of ventilator-associated
pneumonia (VAP) patients were modeled. Patients were
assumed to be treated with doripenem, imipenem or
piperacillin/tazobactam as ﬁrst-line therapy for NP. Clinical
cure and utilization data, including receipt of concomitant
medications (vancomycin/amikacin), days on mechanical venti-
lation (MV), ICU days, and LOS in hospital, were estimated
by combining data from two randomized, multicenter, non-
inferiority clinical trials of doripenem. Wholesale acquisition
costs were used for study drug; costs of MV, ICU and ward
days were estimated from published literature. The primary
outcomes were total costs and incremental cost per clinical
cure. Robustness of the baseline cost-effectiveness analysis was
evaluated using one-way and probabilistic sensitivity analyses
(PSA). RESULTS: In base-case analyses, initial treatment with
doripenem was least costly at $42,041/treated patient, followed
by piperacillin/tazobactam ($43,743), and imipenem ($44,834).
Doripenem dominated piperacillin/tazobactam by being less
costly with a higher probability of clinical cure (72.3% vs.
67.8%). Imipenem had a clinical cure rate of 72.6%, but at an
additional cost of $992,200/cure. Results among the subset of
VAP patients were similar. One-way sensitivity analyses show
the model to be most sensitive to changes in the probability of
cure with each therapy. Probabilistic sensitivity analysis results
indicate that doripenem is cost saving versus imipenem in
77.1% and versus piperacillin/tazobactam in 70.6% of 1,000
iterations. CONCLUSION: First-line therapy with doripenem
yields lower costs and similar efﬁcacy compared to common
NP treatments. Doripenem is a cost-effective treatment for NP
versus imipenem and piperacillin/tazobactam.
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OBJECTIVE: To assess differences in serial mean utility scores,
from Health Utilities Index (HUI) Mark 3 (HUI3) measurements
for patients undergoing treatment for acute lymphoblastic leuke-
mia (ALL) in childhood. These scores will be used for identifying
determinants of health. METHODS: Patients were aged 5 years
or older at time of health-related quality of life (HRQL) survey
and enrolled in the Dana Farber Cancer Institute 95–001 clinical
trial. Parents-of-patients completed self-administered HUI ques-
tionnaires during the four major phases of treatment: induction
of remission (t1); CNS prophylaxis (t2); intensiﬁcation (t3); and
maintenance (t4). HRQL scores are on a scale where 0.00 equals
dead and 1.00 equals perfect health. Signiﬁcant differences
between treatment phases, for mean HRQL and single-attribute
utility scores, were assessed using 1-way ANOVA and paired
t-test. Magnitude of change in mean HRQL scores between
treatment phases was assessed by effect size. Differences in mean
HRQL scores of >0.03 are clinically important. RESULTS: A
total of 375 patients were surveyed (55.2% males). Patients with
complete sets of parental measurements at all treatment phases
were included in this analysis (n = 86). Mean HRQL score
at t1 = 0.68 (SD = 0.306), t2 = 0.74 (SD = 0.245), t3 = 0.77
(SD = 0.267), and t4 = 0.88 (SD = 0.204) (p < 0.001). There was
substantial inter-patient variability in HRQL scores within treat-
ment phases. The effect sizes were 0.200 for t2-t1, 0.120 for t3-t2
and 0.395 for t4-t3. Mean HRQL change scores were 0.06 for t1
to t2 (p = 0.085), 0.03 for t2 to t3 (p = 0.416), and 0.10 for t3 to
t4 (p = 0.001). For single-attribute scores signiﬁcant differences
between treatment phases were observed for ambulation
(p < 0.001), emotion (p < 0.001), pain (p < 0.001). CONCLU-
SION: Mean HRQL, ambulation, emotion and pain scores gen-
erally improved over time. The large inter-patient variability may
reﬂect, in part, the considerable heterogeneity of treatment-
related side effects among patients. Further analyses will explore
whether demographic or diagnostic risk factors contribute to this
variability.
PR2
VALIDATION OFTHE PATIENT HEALTH QUESTIONNAIRE IN
BRFSS—APPLICATION OF CROSS-VALIDATION METHOD
Yeh Y
Mapi Values, Boston, MA, USA
OBJECTIVE: Research has shown that the individuals with
diabetes have a higher chance of being depressed compared to
those without diabetes. To provide effective interventions for
diabetes with depression, practitioners need a reliable and valid
instrument to examine patients’ levels of depression. The
purpose of the study was to evaluate the psychometric proper-
ties of the Patient Health Questionnaire (PHQ) in 2006 Behav-
ioral Risk Factor Surveillance System (BRFSS). METHODS:
The BRFSS is an on-going telephone health survey system,
recording U.S. adults’ health and risk behaviors yearly. The
PHQ measures the depressive symptom that subjects have had
over the last two weeks. In the current investigation, only
Washington residents who were under diabetic treatment(s)
and completed the questionnaire were included in the analyses.
Of 750 subjects in the analyses, 338 (45.07%) were male and
412 (54.93%) were female. The average age was 63.18 years
(SD = 12.53). The split-half, cross-validation method was
applied to assess the psychometric properties of the PHQ.
RESULTS: Exploratory factor analysis was ﬁrst conducted to
determine the measurement structure with the ﬁrst half of the
sample on the ﬁrst step. A one-component solution was
obtained. All items loaded heavily on the target component.
Cronbach coefﬁcient Alpha was 0.82, suggesting good internal
consistency. The second step involved an examination of the
cross-validation of the measurement structures from ﬁrst step
with the second half of the sample using conﬁrmatory factor
analysis procedures. The one-factor model ﬁtted the data well,
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